Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years

Archives of Neurology

Volumn 68, Issue 11, 2011, Pages 1412-1420

  Kim, Su Hyun ^a   Kim, Woojun ^a   Li, Xue Feng ^a   Jung, In Ja ^a   Kim, Ho Jin ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; MITOXANTRONE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD27+ MEMORY B CELL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LOWER RESPIRATORY TRACT INFECTION; MAINTENANCE THERAPY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEMORY CELL; MYELOOPTIC NEUROPATHY; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RETREATMENT; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTE SUBSETS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053457747     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.154     Document Type: Article

References (38)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114. (Pubitemid 29442132)
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112. (Pubitemid 39626806)
3. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197-2200.
4. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566-569. (Pubitemid 43358081)
5. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the longterm course of neuromyelitis optica. Brain. 2008;131(pt 11):3072-3080.
6. Weinstock-Guttman B, Miller C, Yeh EA, et al. Neuromyelitis optica immunoglobulins as amarker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler. 2008;14(8):1061-1067.
7. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009;386(4):623-627.
8. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630-643.
9. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617-629.
10. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133(pt 2):349-361.
11. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5(7):564-576. (Pubitemid 43971191)
12. Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford). 2005;44(2):151-156. (Pubitemid 40277394)
13. Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci. 2005;1050:124-133. (Pubitemid 41129429)
14. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272.
15. Jacob A,Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-1448.
16. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-3908. (Pubitemid 350262316)
17. Tangye SG, Good KL. Human IgM+CD27+B cells: memory B cells or "memory"B cells? J Immunol. 2007;179(1):13-19. (Pubitemid 46986510)
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489. (Pubitemid 43958540)
19. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. (Pubitemid 47238676)
20. Collins-Burow B, Santos ES. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Rev Anticancer Ther. 2007;7(3):257-273. (Pubitemid 46499210)
21. Smolen JS, Keystone EC, Emery P, et al. Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):143-150. (Pubitemid 46226045)
22. Kim HJ, Li XF, Kim W, et al. Quantitative measurement of anti-aquaporin-4 antibody by enzyme-linked immunosorbent assay using purified human aquaporin- 4 [abstract P-60]. Mult Scler. 2010;16:1290.
23. Mahmood NA, Silver K, Onel K, Ko M, Javed A. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol. 2011;26(2):244-247.
24. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613-620. (Pubitemid 43228639)
25. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58(6):1566-1575. (Pubitemid 351847509)
26. Dalakas MC. Invited article: inhibition of B cell functions. implications for neurology. Neurology. 2008;70(23):2252-2260.
27. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501-513. (Pubitemid 40216314)
28. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286-293.
29. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199(12):1659-1669. (Pubitemid 38821999)
30. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial [published correction appears in Ann Neurol. 2008;63(6):803]. Ann Neurol. 2008;63(3):395-400. (Pubitemid 351499869)
31. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebocontrolled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-1400.
32. Cohen SB, Emery P, Greenwald MW, et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806. (Pubitemid 44497758)
33. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 2007;46(4):626-630. (Pubitemid 46523308)
34. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54(3):723-732.
35. St Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum. 2010;62(1):1-5.
36. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113 (20):4834-4840.
37. Rubbert-Roth A, Tak PP, Zerbini C, et al. MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49(9):1683-1693.
38. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 2010;62(5):1273-1279.